Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
X-linked recessive ocular albinism (XLOA) is a rare disorder characterized by ocular hypopigmentation, foveal hypoplasia, nystagmus, photodysphoria, and reduced visual acuity in males.
Features include always present findings: Reduced visual acuity; and very common findings: Nystagmus, Photophobia, Ocular albinism, and Astigmatism and others. 17 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Eyes | 6 | Nystagmus, Nystagmus-induced head nodding, Ocular albinism |
GPR143 encodes G protein-coupled receptor 143 (404 aa). Receptor for tyrosine, L-DOPA and dopamine. Highest expression in Brain Caudate basal ganglia (6.5 TPM) and Brain Nucleus accumbens basal ganglia (6.4 TPM).
X-linked recessive ocular albinism is associated with mutations in the GPR143 gene on chromosome X.
The GPR143 protein participates in MITF-M-dependent GPR143 expression, MITF-M-dependent BCL2 expression, and Regulation of MITF-M-dependent genes involved in pigmentation pathways.
GPR143 is classified as a druggable target (G Protein Coupled Receptor and Transporter categories) with score 0.0.
Genetic testing for GPR143 is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 1 always present feature, 6 very common features, 4 common features.
Estimated prevalence: 1-9 in 1,000,000 (Rare).
No clinical trials have been registered for X-linked recessive ocular albinism.
8 publications have been identified in PubMed for X-linked recessive ocular albinism. Research spans Case Report / Case Series (38%), Basic Science / Preclinical (38%), and Review / Meta-Analysis (13%).
Chen S (2025). [PMID: 41025874](https://pubmed.ncbi.nlm.nih.gov/41025874/). *Invest Ophthalmol Vis Sci*. [Epidemiology / Natural History]
Monteiro M (2025). [PMID: 41426868](https://pubmed.ncbi.nlm.nih.gov/41426868/). *Cureus*. [Case Report / Case Series]
Ramtohul P (2025). [PMID: 39948403](https://pubmed.ncbi.nlm.nih.gov/39948403/). *Eye (London, England)*. [Case Report / Case Series]
Gong X (2025). [PMID: 40232708](https://pubmed.ncbi.nlm.nih.gov/40232708/). *Invest Ophthalmol Vis Sci*. [Basic Science / Preclinical]
Flynn E (2025). [PMID: 41180145](https://pubmed.ncbi.nlm.nih.gov/41180145/). *Journal of vitreoretinal diseases*. [Case Report / Case Series]
Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 6:55 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about X-linked recessive ocular albinism
1 |
Neoplasm of the skin |
Kim YJ (2024). [PMID: 39509688](https://pubmed.ncbi.nlm.nih.gov/39509688/). *ACS chemical neuroscience*. [Basic Science / Preclinical]
Wang F (2024). [PMID: 39228912](https://pubmed.ncbi.nlm.nih.gov/39228912/). *Frontiers in molecular biosciences*. [Review / Meta-Analysis]
Guha S (2024). [PMID: 38798688](https://pubmed.ncbi.nlm.nih.gov/38798688/). *bioRxiv : the preprint server for biology*. [Basic Science / Preclinical]